AI Article Synopsis

  • Many cellular signaling pathways play a crucial role in regulating important processes such as cell growth, movement, and programmed cell death, and their disruption can lead to cancer development and progression.
  • Recent research has highlighted the potential of natural products, like quercetin—a flavonol found in everyday foods—as effective agents in cancer treatment due to their ability to inhibit tumor growth through various mechanisms.
  • This summary focuses on the therapeutic benefits of quercetin specifically in gastrointestinal cancers, including pancreatic, gastric, colorectal, esophageal, hepatocellular, and oral cancers.

Article Abstract

Many cellular signaling pathways contribute to the regulation of cell proliferation, division, motility, and apoptosis. Deregulation of these pathways contributes to tumor cell initiation and tumor progression. Lately, significant attention has been focused on the use of natural products as a promising strategy in cancer treatment. Quercetin is a natural flavonol compound widely present in commonly consumed foods. Quercetin has shown significant inhibitory effects on tumor progression various mechanisms of action. These include stimulating cell cycle arrest or/and apoptosis as well as its antioxidant properties. Herein, we summarize the therapeutic effects of quercetin in gastrointestinal cancers (pancreatic, gastric, colorectal, esophageal, hepatocellular, and oral).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019477PMC
http://dx.doi.org/10.3389/fphar.2022.860209DOI Listing

Publication Analysis

Top Keywords

gastrointestinal cancers
8
tumor progression
8
application quercetin
4
quercetin treatment
4
treatment gastrointestinal
4
cancers cellular
4
cellular signaling
4
signaling pathways
4
pathways contribute
4
contribute regulation
4

Similar Publications

Background: Anastomotic leakage (AL) is a major complication in colorectal surgery, particularly following rectal cancer surgery, necessitating effective prevention strategies. The increasing frequency of colorectal resections and anastomoses during cytoreductive surgery (CRS) for peritoneal carcinomatosis further complicates this issue owing to the diverse patient populations with varied tumor distributions and surgical complexities. This study aims to assess and compare AL incidence and associated risk factors across conventional colorectal cancer surgery (CRC), gastrointestinal CRS (GI-CRS), and ovarian CRS (OC-CRS), with a secondary focus on evaluating the role of protective ostomies.

View Article and Find Full Text PDF

Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer.

J Nanobiotechnology

January 2025

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Biotechnology Center, School of Pharmacy, The Fourth Military Medical University, 169 Changle West Road, 710032, Xi'an, People's Republic of China.

CDK4/6i, the first-line drug for treating ERα-positive breast cancer, significantly improves clinical outcomes. However, CDK4/6i resistance often develops and remains a major hurdle, and the underlying mechanisms remain challenging to fully investigate. Here, we used Genome-wide CRISPR/Cas9 library screening combined with single-cell sequencing to screen for molecules mediating CDK4/6i resistance and identified METTL14 as a determinant of CDK4/6i sensitivity.

View Article and Find Full Text PDF

Gastrointestinal tract-related cancers pose a significant health burden, with high mortality rates. In order to detect the anomalies of the gastrointestinal tract that may progress to cancer, a video capsule endoscopy procedure is employed. The number of video capsule endoscopic ( ) images produced per examination is enormous, which necessitates hours of analysis by clinicians.

View Article and Find Full Text PDF

This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.

View Article and Find Full Text PDF

The identification of immune environments and cellular interactions in the colon microenvironment is essential for understanding the mechanisms of chronic inflammatory disease. Despite occurring in the same organ, there is a significant gap in understanding the pathophysiology of ulcerative colitis (UC) and colorectal cancer (CRC). Our study aims to address the distinct immunopathological response of UC and CRC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!